Other important mutations include those associated with the nuclear factor kappa light-chain-enhancer of activated B cells (NF-kB) activation (occurring in about 14% of MM), G1/S cell cycle transition (occurring in about 5% of MM), Ras-Raf-MEK-ERK pathway (MEK/ERK) signaling, RNA processing, and epigenetic regulators [1,15] (Table 3). The gene discussed is MAP2K7; the disease is Miyoshi myopathy.